Tishman Speyer

United Statestishmanspeyer.com

Its role Developer

project tracked
1
partner companies
5
news articles
2

Tishman Speyer is a prominent real estate investment and development firm based in the United States. The company focuses on creating and managing high-quality commercial, residential, and mixed-use properties in major cities globally. Its main activities include property acquisition, development, leasing, and asset management, often utilizing advanced construction techniques and sustainable building practices.

Read more

With a history dating back decades, Tishman Speyer has been involved in significant projects such as the development phases of research campuses and other large-scale initiatives. It operates primarily in the United States but extends its reach to international markets in Europe and Asia through strategic partnerships and investments.

The ownership structure is private, rooted in family traditions but now involving various institutional investors. This allows the company to pursue long-term value creation rather than quarterly performance pressures common in public companies.

In the competitive real estate industry, Tishman Speyer holds a strong position due to its track record of successful developments and its ability to collaborate with entities like universities and pharmaceutical companies for specialized projects. Its contributions help drive economic development and innovation hubs in the regions it serves.

The project Tishman Speyer is involved in

chemXplore tracks 1 project involving Tishman Speyer.

Roche Genentech Innovation Center Boston
Phase
Operational / Completed
Where
United States
Partners
Bellco Capital , Breakthrough Properties , Genentech , Otera Capital , Roche

Tishman Speyer in chemical industry news

22 October 2026
Roche: Group sales +6% (CER) YTD; Q3 +7% (CER) and +8% in CHF

Group sales +6% (CER) in first nine months; Q3 +7% (CER)/+8% CHF. Pharmaceuticals drove growth, diagnostics up despite China pricing reforms. 2026 outlook confirmed.

17 September 2026
Roche Genentech Innovation Center Boston opens in Allston

Allston hub will focus on cardiovascular, renal and metabolic R&D, combine discovery-to-clinical work with AI and data science, and is part of a USD 50bn US investment programme.

Where its projects are

active all projects